Sign in Create account

Orchid Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ORCHPHARMA BSE: 524372
₹997.00
▼ -17.90 (-1.76%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
50/100
Moderate
Valuation
20/100
Expensive
Momentum
32/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai. It was founded by Kailasam Raghavendra Rao on 1 July 1992. Orchid Pharma is the only pharma company in India to have discovered a New Drug (NCE) Enmetazobactam which is now approved in United States, Europe and India.

Source: Wikipedia

Key Metrics

Market Capitalization
₹5,057 Cr
PE (TTM)
148.1
Industry median 36.1 (152 companies)
Price to Book
4.0
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
21.56%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
8.8
Relative return vs Sector, qtr %
2.3
Free Cash Flow
₹-147 Cr
as of Sept. 30, 2025
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-44.57%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-59.78%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
9.94%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-34.40%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
75.89%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.83
as of March 31, 2025
Industry median 1.84 (197 companies)
Debt to Equity
0.14
as of March 31, 2025
Industry median 0.14 (186 companies)
Interest Coverage
4.52
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
3.92%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
4.65%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
5.31%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.90%
as of March 31, 2025
Industry median 5.54% (180 companies)
Return on Capital Employed
7.85%
as of March 31, 2025
Industry median 12.43% (181 companies)
Return on Equity
7.86%
as of March 31, 2025
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.14)
  • No Return on equity is 15% or more (7.9%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.8%
Low 990.0000 · High 1034.4000
1W return
-9.5%
Low 990.0000 · High 1141.0000
1M return
2.7%
Low 931.1000 · High 1143.5000
52W return
38.4%
Low 480.0000 · High 1143.5000
Lifetime High ₹2527.9000 (April 1, 2021)
Lifetime Low ₹18.0000 (Nov. 3, 2020)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
1026.9
10D
1030.8
20D
1020.5
50D
995.3
100D
939.1
200D
799.3

Delivery and volume

Day avg. delivery
41.7%
Week avg. delivery
45.4%
Month avg. delivery
40.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1007.13
Pivot
First resistance1024.27
Second resistance1051.53
Third resistance1068.67
First support979.87
Second support962.73
Third support935.47
Day RSI47.1
Day MFI73.3
Day MACD13.24
Day MACD signal13.85

Beta

1M0.84
3M-0.29
1Y1.11
3Y0.94

Price change analysis

↑ 2.7%
Over 1 Month
LowHigh
931.101143.50
↑ 2.3%
Over 3 Months
LowHigh
916.751143.50
↑ 92.0%
Over 6 Months
LowHigh
498.101143.50
↑ 38.4%
Over 1 Year
LowHigh
480.001143.50
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 148.1 (own history: 48.6–144.5)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹304 Cr
Net profit (June 30, 2026)
₹12 Cr
Basic EPS (June 30, 2026)
₹1.9900

Ranks #59 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter69.84%
  • Mutual funds19.93%
  • FII/FPI0.81%
  • Other DII0.82%
  • Public8.60%

Largest holders

NameCategoryShares %Shares
Dhanuka Laboratories LimitedPromoter69.8400%35419957
QUANT MUTUAL FUND - QUANT SMALL CAP FUNDPublic6.8300%3465947
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND AND 7 OTHERSPublic4.6000%2335445
UTI SMALL CAP FUND AND 3 OTHERSPublic3.4600%1755037
INVESCO INDIA CONTRA FUND AND 2 OTHERSPublic2.8700%1456510

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 69.84% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.87% to 0.81% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 19.43% to 19.93% in Jun 2026 qtr

6 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 4 insider trades, 14 SAST, 5 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
25 Jan 2022 M/s Dhanuka Laboratories Limited Promoter Pledge Revoke 0 ₹309.64 Cr
21 Jan 2022 M/s Dhanuka Laboratories Limited Promoter Pledge Revoke 0 ₹498.48 Cr
2 Jul 2021 M/s Dhanuka Laboratories Limited Promoter Pledge 0 ₹1,100.00 Cr
27 Jun 2021 M/s Dhanuka Laboratories Limited Promoter Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 267 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 May 2025 UTI MUTUAL FUND Bulk Buy 366,507 615.3700 NSE
28 Nov 2023 UTI MUTUAL FUND Bulk Buy 445,000 571.0000 BSE
28 Nov 2023 DHANUKA LABORATORIES LIMITED Bulk Sell 1,300,000 571.2800 BSE
3 Jan 2018 FORTUNE INTERCONTINENTAL PVT LTD Bulk Sell 470,000 20.3000 BSE
24 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 523,982 68.8700 BSE
24 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 523,982 68.8200 BSE
19 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 391,823 62.3200 BSE
19 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 391,823 62.5500 BSE
12 Mar 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 576,853 88.3300 BSE
12 Mar 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 577,236 88.3100 BSE

All bulk and block deals →

Corporate Actions

Full history (7 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Orchid Chemicals & Pharmaceuticals to Orchid Pharma Limited
2 Aug 2023OTHERAnnual General Meeting
22 Dec 2022OTHERExtra Ordinary General Meeting
6 Jul 2022OTHERAnnual General Meeting
4 Aug 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
1 Aug 2026 Other business matters —
25 May 2026 Financial Results Yes
11 Feb 2026 Financial Results Yes
11 Nov 2025 Financial Results Yes

Corporate Announcements

All 444 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
3 Oct 2026 AGM/EGM Orchid Pharma Ltd - 524372 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct 2026 Shareholders meeting Orchid Pharma Limited has submitted the Exchange a copy Srutinizers report of 33rd Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.
29 Sep 2026 Shareholders meeting Orchid Pharma Limited has informed the Exchange regarding Proceedings of the 33rd Annual General Meeting held on September 29, 2026
29 Sep 2026 AGM/EGM Orchid Pharma Ltd - 524372 - Shareholder Meeting / Postal Ballot-Outcome of AGM
28 Sep 2026 Insider Trading / SAST Orchid Pharma Ltd - 524372 - Closure of Trading Window
28 Sep 2026 Trading Window Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
23 Sep 2026 Updates Orchid Pharma Limited has informed the Exchange regarding 'Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation'.
22 Sep 2026 Updates Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI ( Listing obligation and Disclosure Requirement) Regulations, 2015'.
21 Sep 2026 Updates Orchid Pharma Limited has informed the Exchange regarding 'Investor Roadshow Scheduled to be held in Mumbai'.
21 Sep 2026 Company Update Orchid Pharma Ltd - 524372 - Investor Roadshow Scheduled To Be Held In Mumbai

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.14)
  • Healthy liquidity (Current Ratio 2.83)
  • Strong revenue growth YoY (75.9%)

Weaknesses

  • Low Return on Equity (7.9%)
  • Thin net profit margin (3.9%)
  • Declining profit YoY (-34.4%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (148.1) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Orchid Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.